Skip to main content

Articles

Page 1 of 29

  1. Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks in adults with immune thrombocytopenia (ITP). This phase III study ...

    Authors: Heng Mei, Xiaofan Liu, Yan Li, Hu Zhou, Ying Feng, Guangxun Gao, Peng Cheng, Ruibin Huang, Linhua Yang, Jianda Hu, Ming Hou, Yazhou Yao, Li Liu, Yi Wang, Depei Wu, Liansheng Zhang…

    Citation: Journal of Hematology & Oncology 2021 14:37

    Content type: Research

    Published on:

  2. B-cell receptor (BCR) antagonists such as the BTK inhibitor ibrutinib have proven to effectively target chronic lymphocytic leukemia (CLL) tumor cells, leading to impressive response rates in these patients. H...

    Authors: Timothy L. Chen, Bonnie Harrington, Jean Truxall, Ronni Wasmuth, Alexander Prouty, Shelby Sloan, Amy M. Lehman, Deepa Sampath, Eric Orlemans, Robert A. Baiocchi, Lapo Alinari, John C. Byrd, Jennifer A. Woyach and Erin Hertlein

    Citation: Journal of Hematology & Oncology 2021 14:36

    Content type: Letter to the Editor

    Published on:

  3. Moxetumomab pasudotox is a recombinant CD22-targeting immunotoxin. Here, we present the long-term follow-up analysis of the pivotal, multicenter, open-label trial (NCT01829711) of moxetumomab pasudotox in pati...

    Authors: Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Tadeusz Robak, Philipp D. le Coutre, Bjørn T. Gjertsen, Xavier Troussard, Gail J. Roboz, Lionel Karlin, Douglas E. Gladstone, Nataliya Kuptsova-Clarkson, Shiyao Liu, Priti Patel, Federico Rotolo, Emmanuel Mitry…

    Citation: Journal of Hematology & Oncology 2021 14:35

    Content type: Research

    Published on:

  4. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Musa Yilmaz, Mansour Alfayez, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Marina Y. Konopleva, Sanam Loghavi, Rashmi Kanagal-Shamanna, Keyur P. Patel, Elias J. Jabbour, Guillermo Garcia‑Manero, Naveen Pemmaraju, Sherry A. Pierce, Issa Ghayas, Nicholas J. Short, Guillermo Montalban-Bravo…

    Citation: Journal of Hematology & Oncology 2021 14:34

    Content type: Correction

    Published on:

    The original article was published in Journal of Hematology & Oncology 2020 13:132

  5. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Senlin Zhao, Yushuai Mi, Bingjie Guan, Binbin Zheng, Ping Wei, Yanzi Gu, Zhengxiang Zhang, Sanjun Cai, Ye Xu, Xinxiang Li, Xuefeng He, Xinyang Zhong, Guichao Li, Zhiyu Chen and Dawei Li

    Citation: Journal of Hematology & Oncology 2021 14:33

    Content type: Correction

    Published on:

    The original article was published in Journal of Hematology & Oncology 2020 13:156

  6. Authors: Dan Jin, Jiwei Guo, Yan Wu, Jing Du, Lijuan Yang, Xiaohong Wang, Weihua Di, Baoguang Hu, Jiajia An, Lingqun Kong, Lei Pan and Guoming Su

    Citation: Journal of Hematology & Oncology 2021 14:32

    Content type: Editor's Note

    Published on:

    The Research to this article has been published in Journal of Hematology & Oncology 2019 12:135

  7. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Arnold Bolomsky, Meike Vogler, Murat Cem Köse, Caroline A. Heckman, Grégory Ehx, Heinz Ludwig and Jo Caers

    Citation: Journal of Hematology & Oncology 2021 14:31

    Content type: Correction

    Published on:

    The original article was published in Journal of Hematology & Oncology 2020 13:173

  8. Histone methylation is a key posttranslational modification of chromatin, and its dysregulation affects a wide array of nuclear activities including the maintenance of genome integrity, transcriptional regulat...

    Authors: Guan-Jun Yang, Ming-Hui Zhu, Xin-Jiang Lu, Yan-Jun Liu, Jian-Fei Lu, Chung-Hang Leung, Dik-Lung Ma and Jiong Chen

    Citation: Journal of Hematology & Oncology 2021 14:30

    Content type: Review

    Published on:

  9. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Zemin Ren, Hildo Lantermans, Annemieke Kuil, Willem Kraan, Fernando Arenzana-Seisdedos, Marie José Kersten, Marcel Spaargaren and Steven T. Pals

    Citation: Journal of Hematology & Oncology 2021 14:29

    Content type: Correction

    Published on:

    The original article was published in Journal of Hematology & Oncology 2021 14:11

  10. Therapeutic antibodies targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis induce potent and durable anti-tumor responses in multiple types of cancers. However, only a subse...

    Authors: Ming Yi, Jing Zhang, Anping Li, Mengke Niu, Yongxiang Yan, Ying Jiao, Suxia Luo, Pengfei Zhou and Kongming Wu

    Citation: Journal of Hematology & Oncology 2021 14:27

    Content type: Research

    Published on:

  11. CD19-targeted chimeric antigen receptor T (CAR T) cell therapy is a promising option to treat relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). However, the majority of CAR T-treated patients will...

    Authors: Yun Liang, Hui Liu, Zheming Lu, Wen Lei, Chaoting Zhang, Ping Li, Aibin Liang, Ken H. Young and Wenbin Qian

    Citation: Journal of Hematology & Oncology 2021 14:26

    Content type: Letter to the Editor

    Published on:

  12. Natural killer/T-cell lymphoma (NKTCL) is a disease with limited treatment options and poor outcomes. Daratumumab monotherapy demonstrated clinical activity in a single-patient case report. We present data fro...

    Authors: Huiqiang Huang, Jun Zhu, Ming Yao, Tae Min Kim, Dok Hyun Yoon, Seok-Goo Cho, Hyeon Seok Eom, Soon Thye Lim, Su-peng Yeh, Yuqin Song, Yok Lam Kwong, Jin Seok Kim, Jie Jin, Yuankai Shi, HyeJin Kim, Min Qing…

    Citation: Journal of Hematology & Oncology 2021 14:25

    Content type: Research

    Published on:

  13. Mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, have been intensely investigated for clinical applications within the last decades. However, the majority of registered clinical trials a...

    Authors: Tian Zhou, Zenan Yuan, Jianyu Weng, Duanqing Pei, Xin Du, Chang He and Peilong Lai

    Citation: Journal of Hematology & Oncology 2021 14:24

    Content type: Review

    Published on:

  14. Fibroblast growth factor receptors (FGFRs) play key roles in promoting the proliferation, differentiation, and migration of cancer cell. Inactivation of FGFRs by tyrosine kinase inhibitors (TKI) has achieved g...

    Authors: Sitong Yue, Yukun Li, Xiaojuan Chen, Juan Wang, Meixiang Li, Yongheng Chen and Daichao Wu

    Citation: Journal of Hematology & Oncology 2021 14:23

    Content type: Review

    Published on:

  15. Genetic heterogeneity of tumor is closely related to its clonal evolution, phenotypic diversity and treatment resistance, and such heterogeneity has only been characterized at single-cell sub-chromosomal scale...

    Authors: Xianbin Su, Linan Zhao, Yi Shi, Rui Zhang, Qi Long, Shihao Bai, Qing Luo, Yingxin Lin, Xin Zou, Shila Ghazanfar, Kun Tao, Guoliang Yang, Lan Wang, Kun-Yan He, Xiaofang Cui, Jian He…

    Citation: Journal of Hematology & Oncology 2021 14:22

    Content type: Letter to the Editor

    Published on:

  16. B7-H3, an immune-checkpoint molecule and a transmembrane protein, is overexpressed in non-small cell lung cancer (NSCLC), making it an attractive therapeutic target. Here, we aimed to systematically evaluate t...

    Authors: Jie Liu, Shuo Yang, Bihui Cao, Guangyu Zhou, Fengjuan Zhang, Yuan Wang, Rixin Wang, Lipeng Zhu, Ya Meng, Cong Hu, Hui Liang, Xu Lin, Kangshun Zhu, Guokai Chen, Kathy Qian Luo, Lijun Di…

    Citation: Journal of Hematology & Oncology 2021 14:21

    Content type: Research

    Published on:

  17. Antibody–drug conjugates (ADCs) are a relatively new class of anticancer agents designed to merge the selectivity of monoclonal antibodies with cell killing properties of chemotherapy. They are commonly descri...

    Authors: Carmen Criscitiello, Stefania Morganti and Giuseppe Curigliano

    Citation: Journal of Hematology & Oncology 2021 14:20

    Content type: Review

    Published on:

  18. TNBC is the most aggressive breast cancer with higher recurrence and mortality rate than other types of breast cancer. There is an urgent need for identification of therapeutic agents with unique mode of actio...

    Authors: Yahui Ding, Xiaoping Chen, Can Liu, Weizhi Ge, Qin Wang, Xin Hao, Mengmeng Wang, Yue Chen and Quan Zhang

    Citation: Journal of Hematology & Oncology 2021 14:19

    Content type: Research

    Published on:

  19. Accurate interpretation of BRCA1/2 variants is critical for risk assessment and precise treatment of breast cancer (BC). Hence, the establishment of an ethnicity-based BRCA1/2 variant database of the Chinese popu...

    Authors: Yun Liu, Honglian Wang, Xin Wang, Jiaqi Liu, Junjian Li, Xiang Wang, Yun Zhang, Zhigang Bai, Qinghua Zhou, Ying Wu, Yi Shen, Xiaoling Weng, Fatao Liu, Jiancheng Guo, Lijun Di, Olivier Gires…

    Citation: Journal of Hematology & Oncology 2021 14:18

    Content type: Letter to the Editor

    Published on:

  20. Exportin 1 (XPO1/CRM1) is a key mediator of nuclear export with relevance to multiple cancers, including chronic lymphocytic leukemia (CLL). Whole exome sequencing has identified hot-spot somatic XPO1 point mutat...

    Authors: Janek S. Walker, Zachary A. Hing, Bonnie Harrington, Jordan Baumhardt, Hatice Gulcin Ozer, Amy Lehman, Brian Giacopelli, Larry Beaver, Katie Williams, Jordan N. Skinner, Casey B. Cempre, Qingxiang Sun, Sharon Shacham, Benjamin R. Stromberg, Matthew K. Summers, Lynne V. Abruzzo…

    Citation: Journal of Hematology & Oncology 2021 14:17

    Content type: Research

    Published on:

  21. Dysregulation of both mitochondrial biogenesis and mitophagy is critical to sustain oncogenic signaling pathways. However, the mechanism of mitophagy in promoting hepatocellular carcinoma (HCC) progression rem...

    Authors: Yahui Zheng, Chong Huang, Lu Lu, Kangkang Yu, Jing Zhao, Mingquan Chen, Lu Liu, Qingfeng Sun, Zhifei Lin, Jianming Zheng, Jinhong Chen and Jubo Zhang

    Citation: Journal of Hematology & Oncology 2021 14:16

    Content type: Research

    Published on:

  22. Attributable to its late diagnosis, early metastasis, and poor prognosis, pancreatic cancer remains one of the most lethal diseases worldwide. Unlike other solid tumors, pancreatic cancer harbors ample stromal...

    Authors: Jinxin Tao, Gang Yang, Wenchuan Zhou, Jiangdong Qiu, Guangyu Chen, Wenhao Luo, Fangyu Zhao, Lei You, Lianfang Zheng, Taiping Zhang and Yupei Zhao

    Citation: Journal of Hematology & Oncology 2021 14:14

    Content type: Review

    Published on:

  23. Several targeted therapies have shown efficacy in patients with advanced gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJC), including anti-angiogenic agents and immune checkpoint inhibito...

    Authors: Anwaar Saeed, Robin Park and Weijing Sun

    Citation: Journal of Hematology & Oncology 2021 14:13

    Content type: Review

    Published on:

  24. Peripheral T cell lymphoma (PTCL) is a rare disease and recent approved drugs for relapsed/refractory (r/r) PTCL provided limited clinical benefit. We conducted this study to evaluate the efficacy and safety o...

    Authors: Yuankai Shi, Jianqiu Wu, Zhen Wang, Liling Zhang, Zhao Wang, Mingzhi Zhang, Hong Cen, Zhigang Peng, Yufu Li, Lei Fan, Ye Guo, Liping Ma, Jie Cui, Yuhuan Gao, Haiyan Yang, Hongyu Zhang…

    Citation: Journal of Hematology & Oncology 2021 14:12

    Content type: Research

    Published on:

  25. The survival and proliferation of multiple myeloma (MM) cells in the bone marrow (BM) critically depend on interaction with stromal cells expressing the chemokine CXCL12. CXCL12 regulates the homing to the BM ...

    Authors: Zemin Ren, Hildo Lantermans, Annemieke Kuil, Willem Kraan, Fernando Arenzana-Seisdedos, Marie José Kersten, Marcel Spaargaren and Steven T. Pals

    Citation: Journal of Hematology & Oncology 2021 14:11

    Content type: Research

    Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2021 14:29

  26. Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major ...

    Authors: Ming Yi, Mengke Niu, Linping Xu, Suxia Luo and Kongming Wu

    Citation: Journal of Hematology & Oncology 2021 14:10

    Content type: Review

    Published on:

  27. Key hepatic molecules linking gut dysbiosis and hepatocarcinogenesis remain largely unknown. Gut-derived gut microbiota contains pathogen-associated molecular patterns (PAMPs) that may circulate into the liver...

    Authors: Yi Zhou, Liang Hu, Wenqing Tang, Dongping Li, Lijie Ma, Hongchun Liu, Shuncai Zhang, Xiaojie Zhang, Ling Dong, Xizhong Shen, She Chen, Ruyi Xue and Si Zhang

    Citation: Journal of Hematology & Oncology 2021 14:9

    Content type: Research

    Published on:

  28. P-type ATPase inhibitors are among the most successful and widely prescribed therapeutics in modern pharmacology. Clinical transition has been safely achieved for H+/K+ ATPase inhibitors such as omeprazole and Na

    Authors: Luca Pagliaro, Matteo Marchesini and Giovanni Roti

    Citation: Journal of Hematology & Oncology 2021 14:8

    Content type: Review

    Published on:

  29. Natural killer (NK) cell is a specialized immune effector cell type that plays a critical role in immune activation against abnormal cells. Different from events required for T cell activation, NK cell activat...

    Authors: Sizhe Liu, Vasiliy Galat, Yekaterina Galat4, Yoo Kyung Annie Lee, Derek Wainwright and Jennifer Wu

    Citation: Journal of Hematology & Oncology 2021 14:7

    Content type: Review

    Published on:

  30. HOMER family scaffolding proteins (HOMER1-3) play critical roles in the development and progression of human disease by regulating the assembly of signal transduction complexes in response to extrinsic stimuli...

    Authors: Qinghua Liu, Lixin He, Siqi Li, Fengyan Li, Guangzheng Deng, Xinjian Huang, Muwen Yang, Yunyun Xiao, Xiangfu Chen, Ying Ouyang, Jinxin Chen, Xuxia Wu, Xi Wang, Libing Song and Chuyong Lin

    Citation: Journal of Hematology & Oncology 2021 14:6

    Content type: Research

    Published on:

  31. Mature B cell neoplasms, previously indolent non-Hodgkin lymphomas (iNHLs), are a heterogeneous group of malignancies sharing similar disease courses and treatment paradigms. Most patients with iNHL have an ex...

    Authors: Melissa Lumish, Lorenzo Falchi, Brandon S. Imber, Michael Scordo, Gottfried von Keudell and Erel Joffe

    Citation: Journal of Hematology & Oncology 2021 14:5

    Content type: Review

    Published on:

  32. Prior chemotherapy and/or underlying morbidity commonly leads to poor mobilisation of hematopoietic stem cells (HSC) for transplantation in cancer patients. Increasing the number of available HSC prior to mobi...

    Authors: Simranpreet Kaur, Anuj Sehgal, Andy C. Wu, Susan M. Millard, Lena Batoon, Cheyenne J. Sandrock, Michelle Ferrari-Cestari, Jean-Pierre Levesque, David A. Hume, Liza J. Raggatt and Allison R. Pettit

    Citation: Journal of Hematology & Oncology 2021 14:3

    Content type: Research

    Published on:

  33. BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the pro...

    Authors: Jing Han, Yang Liu, Sen Yang, Xuan Wu, Hongle Li and Qiming Wang

    Citation: Journal of Hematology & Oncology 2021 14:1

    Content type: Review

    Published on:

  34. T cell lymphomas (TCL) comprise a heterogeneous group of non-Hodgkin lymphomas (NHL) that often present at an advanced stage at the time of diagnosis and that most commonly have an aggressive clinical course. ...

    Authors: Katarzyna Iżykowska, Karolina Rassek, Dorota Korsak and Grzegorz K. Przybylski

    Citation: Journal of Hematology & Oncology 2020 13:176

    Content type: Review

    Published on:

  35. As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and t...

    Authors: Liang Wang, Lin-rong Li and Ken H. Young

    Citation: Journal of Hematology & Oncology 2020 13:175

    Content type: Review

    Published on:

  36. Immunotherapy has been a new standard for recurrent/metastatic head and neck cancers (R/M HNC). One of the prominent characteristics of cancer immunotherapy is the induction of immune memory followed by endure...

    Authors: Gaili Chen, Qiuji Wu, Huangang Jiang, Zheng Li, Xinying Hua, Xiaoyan Hu, Haijun Yu, Conghua Xie and Yahua Zhong

    Citation: Journal of Hematology & Oncology 2020 13:174

    Content type: Letter to the Editor

    Published on:

  37. Cell death escape is one of the most prominent features of tumor cells and closely linked to the dysregulation of members of the Bcl-2 family of proteins. Among those, the anti-apoptotic family member myeloid ...

    Authors: Arnold Bolomsky, Meike Vogler, Murat Cem Köse, Caroline A. Heckman, Grégory Ehx, Heinz Ludwig and Jo Caers

    Citation: Journal of Hematology & Oncology 2020 13:173

    Content type: Review

    Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2021 14:31

  38. Hematopoietic reprogramming holds great promise for generating functional target cells and provides new angle for understanding hematopoiesis. We reported before for the first time that diverse differentiated ...

    Authors: Yi Zhou, Chuijin Wei, Shumin Xiong, Liaoliao Dong, Zhu Chen, Sai-Juan Chen and Lin Cheng

    Citation: Journal of Hematology & Oncology 2020 13:171

    Content type: Letter to the Editor

    Published on:

  39. Proteomic characterization of cancers is essential for a comprehensive understanding of key molecular aberrations. However, proteomic profiling of a large cohort of cancer tissues is often limited by the conve...

    Authors: Yangying Zhou, T. Mamie Lih, Jianbo Pan, Naseruddin Höti, Mingming Dong, Liwei Cao, Yingwei Hu, Kyung-Cho Cho, Shao-Yung Chen, Rodrigo Vargas Eguez, Edward Gabrielson, Daniel W. Chan, Hui Zhang and Qing Kay Li

    Citation: Journal of Hematology & Oncology 2020 13:170

    Content type: Research

    Published on:

  40. Acquired epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance limits the long-term clinical efficacy of tyrosine kinase-targeting drugs. Although most of the mechanisms of acquired ...

    Authors: Yulong Fu, Yang Zhang, Zhe Lei, Ting Liu, Tingting Cai, Anqi Wang, Wenwen Du, Yuanyuan Zeng, Jianjie Zhu, Zeyi Liu and Jian-an Huang

    Citation: Journal of Hematology & Oncology 2020 13:169

    Content type: Research

    Published on:

  41. The aberrant Wnt/β-catenin signaling pathway facilitates cancer stem cell renewal, cell proliferation and differentiation, thus exerting crucial roles in tumorigenesis and therapy response. Accumulated investi...

    Authors: Ya Zhang and Xin Wang

    Citation: Journal of Hematology & Oncology 2020 13:165

    Content type: Review

    Published on:

Annual Journal Metrics

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here